Is Jubilant Ingrevia's 3x revenue goal just a pipe dream?

Jubilant Ingrevia might be small, but that's not stopping the small-cap chemicals company from dreaming big. The company has set an audacious target: triple its revenue and quadruple EBITDA within five years, i.e., by FY29. That means sales of around Rs 12,000-13,000 crore from around Rs 4,000 crore and EBITDA of Rs 2,400 crore from Rs 456 crore. Achieving this massive goal will also require doubling its EBITDA margin from 11 per cent in FY24 to over 20 per cent. It's only natural to examine just how achievable the ambitious plan is. Let's begin. What's the game plan? Betting on higher-margin specialty chemicals: The primary strategy to grab higher sales is to ride the demand for specialty chemicals, where Jubilant is pivoting to. Currently, it earns nearly one-fourth of revenue from this category. The global specialty chemicals market, valued at over $641 billion in 2023, is expected to grow 5.2 per cent annually until 2030. The Indian specialty sector is estimated to grow at a faster clip of 9.3 per cent over this stretch. The 'China plus one' shift is further